CHANDAR RAJA ABBOY
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Critical Care Medicine
- Where
- FLORENCE, SC
- NPI
- 1275583585
- Received
- $390,106 in 85 records, 2019 to 2025 ($12,663 general, $377,443 research)
- As principal investigator
- $4,390,942 of research payments to others in 163 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 21 | $11,901 |
| 2025 | Research payment | 13 | $2,133 |
| 2024 | General payment | 2 | $49 |
| 2024 | Research payment | 1 | $5,252 |
| 2023 | General payment | 2 | $38 |
| 2023 | Research payment | 1 | $368,558 |
| 2021 | General payment | 1 | $17 |
| 2020 | General payment | 1 | $17 |
| 2019 | General payment | 41 | $639 |
| 2019 | Research payment | 2 | $1,500 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 20 | $385,600 | 2023–2025 |
| GlaxoSmithKline, LLC. | 18 | $2,198 | 2019–2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,500 | 2019 |
| Sunovion Pharmaceuticals Inc. | 8 | $88 | 2019 |
| Actelion Pharmaceuticals US, Inc. | 4 | $75 | 2019 |
| Merck Sharp & Dohme LLC | 3 | $66 | 2019–2025 |
| AstraZeneca Pharmaceuticals LP | 4 | $64 | 2019 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 | 2019 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $60 | 2019 |
| ABIOMED | 1 | $59 | 2025 |
| Philips North America LLC | 3 | $53 | 2019 |
| Grifols USA, LLC | 2 | $37 | 2019 |
| Mylan Specialty L.P. | 2 | $34 | 2019–2020 |
| Electromed, Inc. | 2 | $33 | 2019–2023 |
| Getinge USA Sales, LLC | 1 | $32 | 2024 |
| Genentech USA, Inc. | 2 | $32 | 2019 |
| Body Vision Medical Inc. | 1 | $22 | 2023 |
| PORTOLA PHARMACEUTICALS, LLC | 1 | $21 | 2019 |
| ResMed Corp | 1 | $17 | 2021 |
| ABBVIE INC. | 1 | $16 | 2024 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 | 2019 |
| Insmed, Inc. | 1 | $12 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 17 | $377,443 |
| Food and Beverage | 49 | $10,825 |
| Travel and Lodging | 17 | $1,786 |
| Education | 2 | $51 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-08 | ABIOMED | $59 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-25 | Merck Sharp & Dohme LLC | $25 | Education | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | 2025 | |
| 2025-04-30 | Merck Sharp & Dohme LLC | $25 | Education | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | 2025 | |
| 2025-02-03 | Eli Lilly and Company | $10,004 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $435 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $269 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $269 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $179 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $179 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $131 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $131 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $60 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $46 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $45 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $13 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $13 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $4 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $2 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $2 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $1 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-03 | Eli Lilly and Company | $0 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-15 | GlaxoSmithKline, LLC. | $347 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $293 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $293 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $284 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $264 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $232 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $79 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $73 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $62 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $59 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $50 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $46 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2025-01-15 | GlaxoSmithKline, LLC. | $45 | Research payment | In-kind items and services | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 | |
| 2024-10-15 | Eli Lilly and Company | $5,252 | Research payment | Cash or cash equivalent | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 | |
| 2024-04-29 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | AVYCAZ Drug, ANTI-INFECTIVE | 2024 | |
| 2024-02-07 | Getinge USA Sales, LLC | $32 | Food and Beverage | In-kind items and services | Cardiohelp Device, Cardiology/Vascular Diseases | 2024 | |
| 2023-06-05 | Electromed, Inc. | $15 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2023 | |
| 2023-05-23 | Body Vision Medical Inc. | $22 | Food and Beverage | Cash or cash equivalent | LungVision Device, Interventional Pulmonology | 2023 | |
| 2023-02-21 | Eli Lilly and Company | $368,558 | Research payment | Cash or cash equivalent | 2023 | ||
| 2021-09-23 | ResMed Corp | $17 | Food and Beverage | In-kind items and services | AirSense Device, Sleep | 2021 | |
| 2020-10-21 | Mylan Specialty L.P. | $17 | Food and Beverage | In-kind items and services | Yupelri Drug, Respiratory and Allergy | 2020 | |
| 2019-11-13 | Sunovion Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | LONHALA MAGNAIR Drug, RESPIRATORY | 2019 | |
| 2019-10-08 | Sunovion Pharmaceuticals Inc. | $10 | Food and Beverage | In-kind items and services | LONHALA MAGNAIR Drug, RESPIRATORY | 2019 | |
| 2019-10-04 | Philips North America LLC | $19 | Food and Beverage | Cash or cash equivalent | inCourage Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-09-27 | Sunovion Pharmaceuticals Inc. | $8 | Food and Beverage | In-kind items and services | LONHALA MAGNAIR Drug, RESPIRATORY | 2019 | |
| 2019-09-06 | Philips North America LLC | $20 | Food and Beverage | Cash or cash equivalent | inCourage Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-08-15 | Electromed, Inc. | $18 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2019 | |
| 2019-05-08 | Sunovion Pharmaceuticals Inc. | $10 | Food and Beverage | In-kind items and services | LONHALA MAGNAIR Drug, RESPIRATORY | 2019 | |
| 2019-05-08 | Sunovion Pharmaceuticals Inc. | $6 | Food and Beverage | In-kind items and services | LONHALA MAGNAIR Drug, RESPIRATORY | 2019 | |
| 2019-05-08 | Sunovion Pharmaceuticals Inc. | $2 | Food and Beverage | In-kind items and services | LONHALA MAGNAIR Drug, RESPIRATORY | 2019 | |
| 2019-04-09 | Insmed, Inc. | $12 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2019 | |
| 2019-04-05 | Regeneron Healthcare Solutions, Inc. | $16 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2019 | |
| 2019-04-03 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | ANORO Drug, RESPIRATORY | 2019 | |
| 2019-04-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2019 | |
| 2019-04-01 | Genentech USA, Inc. | $16 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2019 | |
| 2019-03-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-03-26 | AstraZeneca Pharmaceuticals LP | $11 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-03-25 | Actelion Pharmaceuticals US, Inc. | $22 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2019 | |
| 2019-03-20 | Grifols USA, LLC | $17 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2019 | |
| 2019-03-19 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2019 | |
| 2019-03-18 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2019 | |
| 2019-03-15 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | 2019 | |
| 2019-03-13 | Actelion Pharmaceuticals US, Inc. | $20 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2019 | |
| 2019-03-11 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | FASENRA Drug, Respiratory | 2019 | |
| 2019-03-07 | Tetraphase Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | Xerava Drug, Complicated Intra-Abdominal Infections | 2019 | |
| 2019-03-05 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000 | Research payment | Cash or cash equivalent | Uloric Drug, Gout/Rheumatology | Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular | 2019 |
| 2019-03-05 | Takeda Pharmaceuticals U.S.A., Inc. | $500 | Research payment | Cash or cash equivalent | Uloric Drug, Gout/Rheumatology | Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular | 2019 |
| 2019-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2019 | |
| 2019-03-01 | Genentech USA, Inc. | $16 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2019 | |
| 2019-02-21 | Grifols USA, LLC | $19 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2019 | |
| 2019-02-20 | PORTOLA PHARMACEUTICALS, LLC | $21 | Food and Beverage | Cash or cash equivalent | ANDEXXA Biological, HEMATOLOGY/NEUROLOGY | 2019 | |
| 2019-02-19 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2019 | |
| 2019-02-18 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-02-15 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FASENRA Drug, Respiratory | 2019 | |
| 2019-02-12 | Sunovion Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | LONHALA MAGNAIR Drug, RESPIRATORY | 2019 | |
| 2019-02-06 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | NUCALA Biological, RESPIRATORY | 2019 | |
| 2019-02-02 | Regeneron Healthcare Solutions, Inc. | $25 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2019 | |
| 2019-01-28 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2019 | |
| 2019-01-21 | Philips North America LLC | $13 | Food and Beverage | Cash or cash equivalent | Trilogy 100 Device, Pulmonary/Respiratory Diseases | 2019 | |
| 2019-01-11 | Actelion Pharmaceuticals US, Inc. | $19 | Food and Beverage | In-kind items and services | OPSUMIT Drug, CARDIOVASCULAR DISORDERS | 2019 | |
| 2019-01-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2019 | |
| 2019-01-07 | Mylan Specialty L.P. | $17 | Food and Beverage | In-kind items and services | Perforomist Drug, Respiratory and Allergy | 2019 | |
| 2019-01-04 | Actelion Pharmaceuticals US, Inc. | $12 | Food and Beverage | In-kind items and services | UPTRAVI Drug, CARDIOVASCULAR DISORDERS | 2019 | |
| 2019-01-02 | Sunovion Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | LONHALA MAGNAIR Drug, RESPIRATORY | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-22 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $4,846 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-12-08 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-12-08 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $6,111 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-10-20 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,362 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-10-20 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-09-29 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-09-03 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-08-18 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $2,506 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-07-28 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $5,280 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-07-28 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $390 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-07-14 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $10,125 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-07-14 | GlaxoSmithKline, LLC. | CARE ACCESS RESEARCH | $10,849 | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | 2025 |
| 2025-07-14 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-07-14 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,750 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-07-14 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,362 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-07-07 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-06-09 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $379,025 | A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF W | 2025 |
| 2025-05-27 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $165 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-05-19 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-05-12 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $4,500 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-05-05 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-04-28 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,362 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-04-02 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-04-02 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $6,679 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-04-02 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $3,949 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-03-10 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $30,976 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-02-10 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $4,220 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-02-10 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $30,976 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-01-28 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $123,224 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-01-27 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $11,314 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-01-27 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $18,580 | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2025 |
| 2025-01-13 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $639 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-01-13 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $438,086 | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2025 |
| 2024-12-09 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $60 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-12-09 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $4,887 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-12-09 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-11-25 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $39,608 | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2024 |
| 2024-11-12 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $2,847 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-10-28 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $5,206 | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2024 |
| 2024-10-15 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,873 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-10-15 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $375 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-10-15 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $100 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-10-02 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,200 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2024 |
| 2024-10-02 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-09-23 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $6,813 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-09-23 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $32,453 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-09-16 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $2,323 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-09-09 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $125 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-09-09 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-08-26 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $22,500 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2024 |
| 2024-08-26 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $3,090 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-08-19 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,079 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-08-12 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $375 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-08-12 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-08-12 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $2,847 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-08-05 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-07-29 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $18,480 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-07-29 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $20,789 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-07-22 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $5,727 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-07-22 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $5,657 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-07-15 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $6,500 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-07-08 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-06-04 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $39,931 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-05-06 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,249 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-03-25 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-03-25 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $2,750 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-03-25 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-03-18 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $39,931 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-03-04 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $4,273 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-03-04 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,857 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-03-04 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $3,095 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-03-04 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-03-04 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $39,931 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-02-26 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $39,931 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-02-26 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,857 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-02-20 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-02-05 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $105,200 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-02-05 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $4,050 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-01-29 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $4,050 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-01-29 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $3,374 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-01-29 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $39,931 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-01-29 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $235 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-01-09 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $11,104 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2024-01-08 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $39,931 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-01-03 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $6,021 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2024 |
| 2024-01-02 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $452,259 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2023-12-18 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $750 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-12-18 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $750 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-12-11 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $14,564 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-12-11 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $750 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-12-11 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $17,345 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-12-11 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $15,488 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-12-11 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $710 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-12-11 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $1,857 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-12-11 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $11,390 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-11-14 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $39,931 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-10-16 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $39,931 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-10-09 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $2,393 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2023-09-25 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $220 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
| 2023-09-18 | SANOFI US SERVICES INC. | CARE ACCESS RESEARCH LLC | $17,345 | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Florence, SC, county Florence County, SC, state South Carolina; placed by its city name.
| Measure | Place (city or town) Florence, SC | County Florence County, SC | State South Carolina |
|---|---|---|---|
| Population B01003 | 40,408 | 137,117 | 5,296,225 |
| Population, 2020 census P1 | 39,899 | 137,059 | 5,118,425 |
| Median age B01002 | 37.8 | 39.4 | 40.2 |
| Under 18 B01001 | 24.9% | 23.5% | 21.4% |
| 65 and over B01001 | 17.8% | 18.1% | 18.9% |
| Households B11001 | 16,413 | 52,856 | 2,117,989 |
| Foreign born B05002 | 5.2% | 3.0% | 5.8% |
| Median household income B19013 | $56,143 | $58,305 | $69,324 |
| Median family income B19113 | $75,952 | $79,101 | $86,707 |
| Per capita income B19301 | $34,306 | $33,071 | $39,236 |
| Poverty rate B17001 | 18.9% | 18.7% | 14.1% |
| Unemployment rate B23025 | 5.4% | 5.6% | 4.9% |
| Civilian labor force B23025 | 19,174 | 63,248 | 2,560,429 |
| Mean commute (minutes) B08013 | 18.7 | 22.0 | 25.6 |
| Bachelor's degree or higher B15003 | 30.4% | 24.4% | 32.1% |
| Housing units B25001 | 19,110 | 62,090 | 2,443,039 |
| Owner-occupied B25003 | 58.4% | 64.5% | 71.9% |
| Renters B25003 | 41.6% | 35.5% | 28.1% |
| Median home value B25077 | $211,400 | $177,900 | $259,000 |
| Median gross rent B25064 | $992 | $954 | $1,180 |
| White, not Hispanic B03002 | 40.5% | 49.1% | 61.9% |
| Black B03002 | 49.8% | 42.9% | 24.6% |
| Hispanic or Latino B03002 | 4.6% | 3.3% | 7.4% |
| Asian B03002 | 3.2% | 1.6% | 1.7% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Florence, SC.
Comments